Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China

This is an interventional prevention trial for Diphtheria focused on measuring Pentaxim®, Whole-cell Pertussis vaccine, Acellular Pertussis vaccine, Haemophilus influenzae type b polysaccharide, Inactivated Polio vaccine, Pentavac® Read More

Inclusion Criteria:

• Aged 2 months (60 to 74 days) inclusive on the day of the first study visit
• Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative
• Subject and parent/legally acceptable representative are able to attend all scheduled visits and to comply with all trial procedures.

Exclusion Criteria:

• Participation or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
• Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy since birth, or long-term systemic corticosteroids therapy (prednisone or equivalent for more than 2 consecutive weeks since birth)
• Known systemic hypersensitivity to any of the vaccine components, or history of a life threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances
• Clinically significant illness, according to investigator judgment, at a stage that could interfere with trial conduct or completion
• Evolving encephalopathy
• Receipt of immune globulins, blood or blood-derived products since birth
• Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis diseases or Haemophilus influenzae type b infection
• Receipt of any other vaccine in the 14 days preceding the first trial vaccination or planned receipt of any vaccine in the 14 days following the first trial vaccination
• Acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (axillary temperature ≥37.1°C). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided.
• Contraindications to vaccination according to PENTAXIM® summary of product characteristics (SPC) or leaflet
• In an emergency setting, or hospitalized involuntarily
• Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study.